Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Clinical trial NCT06796803 · RECRUITING
Trial details
- NCT number
- NCT06796803
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-20
- Primary completion
- 2028-02-20
- Enrollment
- 398
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.